NEWPORT BEACH, Calif., Jan. 10, 2012 /PRNewswire/ -- On December 21, 2011 Cannabis Science, Inc. (OTCBB:CBIS.OB) reported many critical ailments of which the Company has identified as part of its ongoing mission to capture the market share. One of which is Cancer with estimated Global drug sales growth at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion by 2012. Conservatively speaking, if the Company is able to capture only 1% (one percent) of the Cancer market, it would translate to approximately $75 (seventy five) million in that segment alone.
If these figures are on the low-end spectrum then the Company's Earnings Guidance on December 29, 2011 could be well under-estimated since their 2012 forecasted only $6,846,000 and potentially $65,740,000 by 2014. It's a bit early to tell if the Company is able to hit these numbers but judging from their earlier successes from recent case studies, the Company is on the right path to accomplish its goals and maybe more.
Evidently, on two separate press releases, the Company reported its brand extracts successful Cancer treatments as reported by Squamous Cell Carcinoma and Skin Cancer self-medicating patients with continued shrinking of Cancer cells.
According to the testimonials, these patients have photo-documented dramatic results that the Company will release to the public once treatment is completed and has been properly vetted by clinical biopsy. The Company, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who were seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed cancer treatment.
Cannabis Science went on to mention that it's making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today's modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.
Also, the Company has already released its first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1. Both are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.
Cannabis Science MT-1: Produced by Marisol Therapeutics: A family-owned shop, Marisol Therapeutics was founded to assist medical marijuana patients in obtaining medical marijuana in Colorado. They believe patients have the right to safe, confidential, quality medical marijuana and products. They recommend medical marijuana from their own experience with unrelenting and previously untreatable pain. "We understand, we care, we want you to heal." Marisal Therapeutics has produced a custom blend of that is derived from their proprietary strains that were developed over 30 years by a Native American Vietnam veteran in order to address his medical needs. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds. The product is produced in soil under organic roof conditions.
ADDRESS: 922 Kimble Drive, Pueblo West, CO 81007
Cannabis Science CT-1: Produced by Cannabis Therapeutics was Colorado's first dispensary. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics is a professional medical business that employs all its policies and regulations to ensure the most stringent adherence to the law. Second in importance to legality is implementation of standardizing techniques to ensure both repeatability in dosing and quality of medicine. Cannabis Therapeutics began as an organization built by individuals that did not receive satisfactory relief from conventional therapies. Cannabis Therapeutics has produced a high quality cannabis extract from a custom blend of buds hydroponically grown medical marijuana strains. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds.
ADDRESS: 907 E Fillmore St., Colorado Springs, CO 80907
http://www.cannabistherapeutics.net/ for more information.
Please visit www.cannabisscience.com to view the "Breaking News" of the successful results and images of the self-administered cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE Cannabis Science, Inc.